French pharmaceutical company Ipsen has signed an agreement to acquire five consumer healthcare products in certain European territories from Sanofi for €83m.

The significant product to be acquired is an analgesic known as Prontalgine, which will be used to treat moderate-to-severe pain that has increased over the last four years.

Ipsen CEO David Meek said: “This tactical bolt-on transaction resulting from the European Commission’s requirement to divest certain assets from the Sanofi / Boehringer Ingelheim consumer healthcare deal strengthens our consumer healthcare portfolio in France with the addition of Prontalgine.

“The opportunity immediately improves the profitability profile of Ipsen’s primary care business. It adds a limited portfolio of well-established and market leading brands in a key market such as France.”

"With these new assets, the primary care business expands its OTx portfolio and enhances its value proposition to consumers."

As part of the agreement, Ipsen will also acquire Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, expectorants for cough and flu.

These regional brands jointly cover a geographic scope of eight countries in Europe, while manufacturing will be provided by third parties.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ipsen Primary Care executive vice-president Jean Fabre said: “With these new assets, the primary care business expands its OTx portfolio and enhances its value proposition to consumers.

“The products are fully synergistic with our existing infrastructure, and the key asset Prontalgine, a well-established and growing market player for pain management in France with mid-30% market share, will help us achieve a critical mass at the pharmacy level, accelerating the development of our consumer healthcare business.”

Subject to customary closing conditions, including the European Commission’s approval, the transaction is expected to close in the second quarter of this year and will be financed completely by Ipsen’s existing cash and lines of credit.